Linc (LINC) Q2 2026 earnings summary

Executive summary

• Substantial recovery in asset values during Q2 2026, driven by strong performance in MedCap and Stille, despite high market volatility and geopolitical uncertainty.

• Net asset value (NAV) per share increased by 6.1% in Q2 2026 and 1.8% for H1 2026, reversing last year's negative trend.

• Portfolio strategy focused on opportunistic, long-term investments in Nordic life science companies with global potential.

Financial highlights

• Q2 2026: Management result SEK 244.5m (367.6m), EBIT SEK 241.1m (364.8m), net profit SEK 258.1m (350.8m), EPS SEK 4.5 (6.1).

• H1 2026: Management result SEK 82.1m (-646.8m), EBIT SEK 75.4m (-653.1m), net profit SEK 81.2m (-645.2m), EPS SEK 1.4 (-11.1).

• NAV at period end SEK 4,508.8m, NAV per share SEK 77.9.

• Solid equity ratio of 99.8%, net cash position of SEK 170.0m.

Outlook and guidance

• Well-positioned to capitalize on market opportunities with a strong balance sheet.

• Continued focus on selective investments in companies with clear clinical and commercial potential.

• Market volatility and geopolitical risks expected to persist.